GSK Expands Respiratory Pipeline With siRNA Pact

SCRIP–GSK is taking a bet on a small-interfering RNA (siRNA) gene silencing asset for lung disease in a new pact with Empirico. The US biotech specializes in siRNA therapies and GSK has acquired worldwide exclusive rights to its Phase I asset, EMP-012, for chronic obstructive pulmonary disease (COPD) via a $85m upfront deal.